logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences has potential to 'revolutionise treatment in monoclonal antibodies market'

Proactive Research analyst Emma Ulker discusses what she describes as the ground-breaking approach Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) is taking in the field of monoclonal antibodies. She says their lead programme Foralumab is notable in that not only is it the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by the company for nasal and oral administration.

Click here to read Tiziana Life Sciences: Transformational potential

Quick facts: Tiziana Life Sciences PLC

Price: 169 GBX

AIM:TILS
Market: AIM
Market Cap: £322.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker

Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...

1 week, 1 day ago

2 min read